Tenax plummets on phase 3 failure of pulmonary hypertension drug

· seekingalpha.com

Tenax Therapeutics plunges 89% after TNX-103 phase 3 failure in PH-HFpEF. Read more here.

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.

If you have an ad-blocker enabled you may be blocked from ...


Read on WOBR AI → · More AI market news · StrategyVerse · Quant Research · WOBR.AI